Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Hexal_AG
gptkb:Eon_Labs Apex Pharma Oriel Therapeutics |
| gptkbp:awards |
various industry awards
|
| gptkbp:clinicalTrials |
conducts numerous
|
| gptkbp:collaborations |
with academic institutions
with research organizations with biotech companies |
| gptkbp:corporateSocialResponsibility |
community engagement
disaster relief efforts education programs environmental sustainability programs healthcare_access_initiatives |
| gptkbp:employeeCount |
over 10,000
|
| gptkbp:focus |
affordable medicines
|
| gptkbp:founded |
1886
|
| gptkbp:founder |
gptkb:Hermann_Sandoz
|
| gptkbp:globalPresence |
operates in over 140 countries
|
| gptkbp:headquarters |
gptkb:Holzkirchen,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sandoz Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:innovation |
focus on biosimilars
development of generic drugs research in complex generics |
| gptkbp:market |
growing_in_Asia
strong_in_Europe expanding_in_North_America |
| gptkbp:mission |
to provide access to high-quality medicines
|
| gptkbp:parentCompany |
Novartis
|
| gptkbp:partnerships |
various healthcare organizations
|
| gptkbp:productLine |
antibiotics
hormonal therapies oncology drugs cardiovascular drugs diabetes medications dermatology products gastrointestinal products respiratory products pain management products central nervous system drugs |
| gptkbp:products |
generic drugs
biosimilars |
| gptkbp:region |
global
|
| gptkbp:regulatoryCompliance |
FDA_approved
EMA_approved |
| gptkbp:researchAndDevelopment |
invests heavily
|
| gptkbp:revenue |
approximately $10 billion
|
| gptkbp:sustainabilityInitiatives |
environmental responsibility
|
| gptkbp:vision |
to be a leader in generic pharmaceuticals.
|
| gptkbp:website |
www.sandoz.com
|